GlobeNewsWire
11 Dec 2025, 13:00 UTC · 40w ago
Verdict
Headline takes no side. We score ELTX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Analysis of a subset of patients in the Phase 2 AMPLIFY-7P trial showed 87% (13/15) induced antigen spreading to non-mKRAS neoantigens.
More positive than 92% of claims this week
Elicio's ELI-002 is an off-the-shelf immunotherapy targeting mKRAS mutations, which drive approximately 25% of all solid tumors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 63% of claims this week
The company intends to expand ELI-002 into other indications, including mKRAS-positive lung cancer.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company reported positive Phase 2 trial data demonstrating that its immunotherapy candidate induced broad antigen spreading in a majority of patients.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
10h ago
−76.8%
Price is moving against the score
$1.87 vs $8.05 close before publication (Dec 10) · not market-adjusted
ELTX chart →
